| Overview |
| bsm-60935r-pe-100l |
| KEAP1 Monoclonal Antibody, PE Conjugated |
| WB, IF |
| Human, Mouse, Monkey |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human KEAP1 |
| Monoclonal |
| 7B13 |
| IgG |
| 1mg/ml |
| purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 9817 |
| Q14145 |
| Cytoplasm, Nucleus |
| Cytosolic inhibitor of Nrf2; INrf 2; INrf2; Keap 1; KEAP1; KEAP1_HUMAN; Kelch like ECH associated protein 1; Kelch like protein 19; Kelch-like ECH-associated protein 1; Kelch-like protein 19; KIAA0132; KLHL 19; KLHL19; MGC10630; MGC1114; MGC20887; MGC4407; MGC9454. |
| Retains NFE2L2/NRF2 in the cytosol. Functions as substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1. Targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. May also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome. |
| Application Dilution |
| WB |
1:500-2000 |
| IF |
1:100-500 |